Eli Lilly and Co
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
A Study in Participants With Acute Leukemia
- Conditions
- Leukemia
- Interventions
- Drug: LY2090314
- First Posted Date
- 2010-10-05
- Last Posted Date
- 2018-11-19
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 20
- Registration Number
- NCT01214603
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Houston, Texas, United States
A Dose-Escalation Study for Patients With Advanced Cancer
- First Posted Date
- 2010-10-05
- Last Posted Date
- 2018-08-06
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 63
- Registration Number
- NCT01214642
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Antonio, Texas, United States
A Study for Patients With Acute Leukemia
- Conditions
- Acute Leukemia
- Interventions
- Drug: LY2523355
- First Posted Date
- 2010-10-05
- Last Posted Date
- 2019-05-13
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 33
- Registration Number
- NCT01214655
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Houston, Texas, United States
A Phase 1 Study of LY2874455 in Participants With Advanced Cancer
- First Posted Date
- 2010-09-30
- Last Posted Date
- 2019-06-12
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 94
- Registration Number
- NCT01212107
- Locations
- 🇰🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seoul, Korea, Republic of
A Tasisulam and Midazolam Drug Interaction Study in Cancer Patients
- First Posted Date
- 2010-09-27
- Last Posted Date
- 2019-03-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 11
- Registration Number
- NCT01209832
- Locations
- 🇫🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rennes, France
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
- Conditions
- Systemic Lupus ErythematosusConnective Tissue DiseaseAutoimmune Disease
- Interventions
- Drug: Placebo every 2 weeksDrug: LY2127399Drug: Placebo every 4 weeks
- First Posted Date
- 2010-09-20
- Last Posted Date
- 2018-07-17
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1124
- Registration Number
- NCT01205438
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., London, United Kingdom
A Study of Olaratumab (IMC-3G3) in Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2010-09-17
- Last Posted Date
- 2019-09-20
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 123
- Registration Number
- NCT01204710
- Locations
- 🇪🇸
ImClone Investigational Site, Valencia, Spain
A Rheumatoid Arthritis Study in Participants
- Conditions
- Rheumatoid Arthritis
- Interventions
- Drug: LY2127399Drug: Placebo
- First Posted Date
- 2010-09-16
- Last Posted Date
- 2018-04-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1004
- Registration Number
- NCT01202760
- Locations
- 🇺🇦
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vinnytsya, Ukraine
A Study in Participants With Rheumatoid Arthritis
- Conditions
- Rheumatoid Arthritis
- Interventions
- Drug: LY2127399Drug: Placebo Q2WDrug: Placebo Q4W
- First Posted Date
- 2010-09-16
- Last Posted Date
- 2018-05-14
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 456
- Registration Number
- NCT01202773
- Locations
- 🇨🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taipei, Taiwan
A Study in Participants With End-Stage Renal Disease
- Conditions
- Kidney Failure, Chronic
- Interventions
- Drug: LY2127399
- First Posted Date
- 2010-09-13
- Last Posted Date
- 2018-05-14
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 18
- Registration Number
- NCT01200290
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Indianapolis, Indiana, United States